Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.

Zinman B, Schmidt WE, Moses A, Lund N, Gough S

Diabetes, obesity & metabolism30 Oct 2011Cited by 81 (Europe PMC)

PMID21883806DOI10.1111/j.1463-1326.2011.01493.xPepBankPUB-21883806

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, 40% on liraglutide 1.8 mg reached HbA1c below 7% without weight gain or hypoglycaemia at 26 weeks, versus 6-25% on comparators.
In plain wordsIn adults with type 2 diabetes, more people on liraglutide 1.8 mg (40%) reached the combined goal than on comparators (6-25%).
Peptide
Liraglutide
Outcome
IncreaseComposite of HbA1c <7% without weight gain or hypoglycaemia
Study
n = 4,625
Comparator
Glimepiride, rosiglitazone, glargine, exenatide, sitagliptin or placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Measurements
Proportion achieving composite outcome
40%
liraglutide 1.8 mg
Source sentences
Summary
At 26 weeks, 40% of the liraglutide 1.8 mg group, 32% of the liraglutide 1.2 mg group and 6-25% of comparators (6% rosiglitazone, 8% glimepiride, 15% glargine, 25% exenatide, 11% sitagliptin, 8% placebo)
1 context sentence(design, population, supporting numbers)
Summary · context
A prespecified meta-analysis was performed on 26-week patient-level data from seven trials (N = 4625) evaluating liraglutide with commonly used therapies for type 2 diabetes: glimepiride, rosiglitazone, glargine, exenatide, sitagliptin or placebo, adjusting for baseline HbA1c and weight, for a compo…
Report a problemFND-2188380601
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, 32% on liraglutide 1.2 mg reached HbA1c below 7% without weight gain or hypoglycaemia at 26 weeks, versus 6-25% on comparators.
In plain wordsIn adults with type 2 diabetes, more people on liraglutide 1.2 mg (32%) reached the combined goal than on comparators (6-25%).
Peptide
Liraglutide
Outcome
IncreaseComposite of HbA1c <7% without weight gain or hypoglycaemia
Study
n = 4,625
Comparator
Glimepiride, rosiglitazone, glargine, exenatide, sitagliptin or placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg · 26 weeksAs given in this study (human).
Measurements
Proportion achieving composite outcome
32%
liraglutide 1.2 mg
Source sentences
Summary
At 26 weeks, 40% of the liraglutide 1.8 mg group, 32% of the liraglutide 1.2 mg group and 6-25% of comparators (6% rosiglitazone, 8% glimepiride, 15% glargine, 25% exenatide, 11% sitagliptin, 8% placebo)
1 context sentence(design, population, supporting numbers)
Summary · context
A prespecified meta-analysis was performed on 26-week patient-level data from seven trials (N = 4625) evaluating liraglutide with commonly used therapies for type 2 diabetes: glimepiride, rosiglitazone, glargine, exenatide, sitagliptin or placebo, adjusting for baseline HbA1c and weight, for a compo…
Report a problemFND-2188380602
03HumanSystematic reviewEfficacy outcome
Odds of reaching the composite outcome were higher with liraglutide 1.8 mg than with each comparator, by 2.0- to 10.5-fold.
In plain wordsPeople on liraglutide 1.8 mg were 2.0 to 10.5 times more likely to reach the combined goal than people on comparator treatments.
Peptide
Liraglutide
Outcome
IncreaseComposite of HbA1c <7% without weight gain or hypoglycaemia
Study
n = 4,625
Comparator
Glimepiride, rosiglitazone, glargine, exenatide, sitagliptin or placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Odds ratios favoured liraglutide 1.8 mg by 2.0- to 10.5-fold over comparators.
1 context sentence(design, population, supporting numbers)
Summary · context
A prespecified meta-analysis was performed on 26-week patient-level data from seven trials (N = 4625) evaluating liraglutide with commonly used therapies for type 2 diabetes: glimepiride, rosiglitazone, glargine, exenatide, sitagliptin or placebo, adjusting for baseline HbA1c and weight, for a compo…
Report a problemFND-2188380603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials7

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

7 trials · 6 completed · 1 stopped early · 4 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00700817